Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07374939 · ClinicalTrials.gov registry record
Medical Cannabis Observational Study for Antiemetic Intervention in Chemotherapy
A clinical trial, sponsored by University of Rochester.
- Not yet
- Registry status
- 50
- Enrollment target
NCT07374939 is a clinical trial that has not yet begun recruiting, run by University of Rochester. The registered enrollment target is 50 participants.
The verdict
NCT07374939 has not yet begun recruiting, sponsored by University of Rochester.
- NOT YET RECRUITING
- Registry status
- 50 participants
- Enrollment target
Study Summary
The goal of this observational study is to evaluate the associations between patient-directed medical cannabis use and chemotherapy-induced nausea and vomiting (CINV), as well as other treatment-related symptoms, among patients receiving chemotherapy that is known to cause nausea. The main questions it aims to answer are: * Is patient-directed medical cannabis use associated with reduced nausea severity during chemotherapy treatment? * Is-patient directed medical cannabis use associated with improved CINV control? * Is patient directed medical cannabis use associated with improved appetite during chemotherapy treatment? * Is patient-medical cannabis use associated with reduced treatment-related side effects, such as fatigue, sleep disturbances, general pain, and peripheral neuropathic pain? Researchers will compare participants who report using medical cannabis with participants who do not report using medical cannabis to determine whether differences exist in nausea, CINV outcomes, and other treatment-related symptoms. Participants will be followed over the course of 3 chemotherapy cycles, and asked to complete questionnaires, nausea diaries, and partake in a blood sample collection. Study participation can last from 6 - 12 weeks, depending on their prescribed chemotherapy cycle frequency.
Interventions
- DRUG Medical Cannabis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2028-03-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07374939
The ClinicalTrials.gov registry entry for NCT07374939 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Medical Cannabis is the first listed.
NCT07374939 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07374939 about?
NCT07374939 is a clinical study titled "Medical Cannabis Observational Study for Antiemetic Intervention in Chemotherapy". The goal of this observational study is to evaluate the associations between patient-directed medical cannabis use and chemotherapy-induced nausea and vomiting (CINV), as well as other treatment-related symptoms, among patients receiving chemotherapy that is known to cause nausea. The main questions...
What is the current status of trial NCT07374939?
This trial is currently not yet recruiting. The enrollment target is 50 participants. The study started on 2026-09-01. Estimated completion is 2028-03-01.
What interventions are being tested in trial NCT07374939?
The interventions under investigation include: Medical Cannabis (DRUG).
Who is sponsoring clinical trial NCT07374939?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.